Computational Systems Analysis of Dopamine Metabolism

A prominent feature of Parkinson's disease (PD) is the loss of dopamine in the striatum, and many therapeutic interventions for the disease are aimed at restoring dopamine signaling. Dopamine signaling includes the synthesis, storage, release, and recycling of dopamine in the presynaptic terminal and activation of pre- and post-synaptic receptors and various downstream signaling cascades. As an aid that might facilitate our understanding of dopamine dynamics in the pathogenesis and treatment in PD, we have begun to merge currently available information and expert knowledge regarding presynaptic dopamine homeostasis into a computational model, following the guidelines of biochemical systems theory. After subjecting our model to mathematical diagnosis and analysis, we made direct comparisons between model predictions and experimental observations and found that the model exhibited a high degree of predictive capacity with respect to genetic and pharmacological changes in gene expression or function. Our results suggest potential approaches to restoring the dopamine imbalance and the associated generation of oxidative stress. While the proposed model of dopamine metabolism is preliminary, future extensions and refinements may eventually serve as an in silico platform for prescreening potential therapeutics, identifying immediate side effects, screening for biomarkers, and assessing the impact of risk factors of the disease.

[1]  L. Vacca,et al.  Symptom relief in Parkinson disease by safinamide , 2006, Neurology.

[2]  Eberhard O. Voit,et al.  Canonical nonlinear modeling : S-system approach to understanding complexity , 1991 .

[3]  E O Voit,et al.  Canonical modeling: review of concepts with emphasis on environmental health. , 2000, Environmental health perspectives.

[4]  T. Chase,et al.  Degradation of α-Synuclein by Proteasome* , 1999, The Journal of Biological Chemistry.

[5]  A. Carlsson,et al.  The occurrence, distribution and physiological role of catecholamines in the nervous system. , 1959, Pharmacological reviews.

[6]  R. Wightman,et al.  Profound neuronal plasticity in response to inactivation of the dopamine transporter. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  H. Ueda,et al.  Supersensitization of intrastriatal dopamine receptors involved in opposite regulation of acetylcholine release in Parkinson's model rats , 1994, Neuroscience Letters.

[8]  M. Savageau.  Biochemical systems analysis. II. The steady-state solutions for an n-pool system using a power-law approximation. , 1969, Journal of theoretical biology.

[9]  R. Palmiter,et al.  Dopamine-Deficient Mice Are Hypersensitive to Dopamine Receptor Agonists , 2000, The Journal of Neuroscience.

[10]  H Ujike,et al.  VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Ira Shoulson,et al.  DATATOP: A decade of neuroprotective inquiry , 1998 .

[12]  Nicolas Le Novère,et al.  DARPP-32 Is a Robust Integrator of Dopamine and Glutamate Signals , 2006, PLoS Comput. Biol..

[13]  Jonas S. Almeida,et al.  Decoupling dynamical systems for pathway identification from metabolic profiles , 2004, Bioinform..

[14]  Beate Ritz,et al.  Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. , 2006, Human molecular genetics.

[15]  J. Andersen.  Iron dysregulation and Parkinson's disease. , 2005, Journal of Alzheimer's disease : JAD.

[16]  J. M. Phillips,et al.  Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. , 2006, The European journal of neuroscience.

[17]  Eberhard O. Voit,et al.  Simulation and validation of modelled sphingolipid metabolism in Saccharomyces cerevisiae , 2005, Nature.

[18]  M. Savageau.  Biochemical systems analysis. II. The steady-state solutions for an n-pool system using a power-law approximation. , 1969, Journal of theoretical biology.

[19]  Vesna Sossi,et al.  Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study , 2007, Annals of neurology.

[20]  Enrique Herrero,et al.  Predictive reconstruction of the mitochondrial iron–sulfur cluster assembly metabolism: I. The role of the protein pair ferredoxin–ferredoxin reductase (Yah1–Arh1) , 2004, Proteins.

[21]  Poorvi Kaushik,et al.  Dynamics of tyrosine hydroxylase mediated regulation of dopamine synthesis , 2007, Journal of Computational Neuroscience.

[22]  K. Bötzel,et al.  Prevalence and incidence of Parkinson's disease in Europe , 2005, European Neuropsychopharmacology.

[23]  M. Savageau.  Biochemical systems analysis. III. Dynamic solutions using a power-law approximation , 1970 .

[24]  Christopher J Langmead,et al.  Muscarinic acetylcholine receptors as CNS drug targets. , 2008, Pharmacology & therapeutics.

[25]  T. Humby,et al.  Age‐related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease , 2006, The European journal of neuroscience.

[26]  L. Pannell,et al.  Enzyme Activity of Macrophage Migration Inhibitory Factor toward Oxidized Catecholamines* , 1999, The Journal of Biological Chemistry.

[27]  J. Andersen,et al.  Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age , 2007, Neurobiology of Aging.

[28]  Gary W. Miller,et al.  Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration , 2007, The Journal of Neuroscience.

[29]  I. Shoulson.  DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. , 1998, Annals of neurology.

[30]  E. Masliah,et al.  alpha-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson disease. , 2008, The Journal of biological chemistry.

[31]  E. Voit,et al.  Recasting nonlinear differential equations as S-systems: a canonical nonlinear form , 1987 .

[32]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[33]  A. Anton,et al.  THE DISTRIBUTION OF DOPAMINE AND DOPA IN VARIOUS ANIMALS AND A METHOD FOR THEIR DETERMINATION IN DIVERSE BIOLOGICAL MATERIAL. , 1964, The Journal of pharmacology and experimental therapeutics.

[34]  M. Karayiorgou,et al.  Effect of Dopamine Uptake Inhibition on Brain Catecholamine Levels and Locomotion in Catechol-O-methyltransferase-Disrupted Mice , 2002, Journal of Pharmacology and Experimental Therapeutics.

[35]  J. Holden,et al.  Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA. , 1997, European journal of pharmacology.

[36]  Eberhard O. Voit,et al.  S-system modelling of complex systems with chaotic input , 1993 .

[37]  M. Savageau.  Biochemical Systems Analysis: A Study of Function and Design in Molecular Biology , 1976 .

[38]  Ping Liu,et al.  Pathogenesis of Parkinson’s disease: oxidative stress, environmental impact factors and inflammatory processes , 2007, Neuroscience Bulletin.

[39]  P. M. Chan,et al.  Mice with Very Low Expression of the Vesicular Monoamine Transporter 2 Gene Survive into Adulthood: Potential Mouse Model for Parkinsonism , 2001, Molecular and Cellular Biology.

[40]  Gilberto Fisone,et al.  DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia. , 2004, Parkinsonism & related disorders.

[41]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[42]  Y. Kakimoto,et al.  Distribution of catechol compounds in human brain. , 1959, Biochimica et biophysica acta.

[43]  D. Graham.  Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.

[44]  S. Przedborski.  Pathogenesis of nigral cell death in Parkinson's disease. , 2005, Parkinsonism & related disorders.

[45]  K. Vrana,et al.  Cytotoxic and genotoxic potential of dopamine , 1999, Journal of neuroscience research.

[46]  D. Goldstein,et al.  Cardiac denervation in patients with Parkinson disease. , 2007, Cleveland Clinic journal of medicine.

[47]  J. M. Phillips,et al.  Blockade of mGluR5 glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease , 2006 .

[48]  D. Schomburg,et al.  BRENDA: a resource for enzyme data and metabolic information. , 2002, Trends in biochemical sciences.

[49]  K Leuner,et al.  The Complexity of the Dopaminergic Synapses and their Modulation by Antipsychotics , 2006, Pharmacopsychiatry.

[50]  Eberhard O. Voit,et al.  Computational Analysis of Biochemical Systems: A Practical Guide for Biochemists and Molecular Biologists , 2000 .

[51]  Arthur R. Schulz,et al.  Enzyme Kinetics: From Diastase to Multi-enzyme Systems , 1994 .

[52]  Jeanette Kotaleski,et al.  Transient Calcium and Dopamine Increase PKA Activity and DARPP-32 Phosphorylation , 2006, PLoS Comput. Biol..

[53]  J. B. Justice,et al.  Modeling the dopaminergic nerve terminal , 1988, Journal of Neuroscience Methods.

[54]  Inactivation of the dopamine transporter reveals essential roles of dopamine in the control of locomotion, psychostimulant response, and pituitary function. , 1998, Advances in pharmacology.

[55]  E. Voit,et al.  Pathway Analysis and Optimization in Metabolic Engineering , 2002 .

[56]  Leslie Greengard,et al.  A mathematical tool for exploring the dynamics of biological networks , 2007, Proceedings of the National Academy of Sciences.

[57]  H. Fernandez,et al.  Monamine Oxidase Inhibitors: Current and Emerging Agents for Parkinson Disease , 2007, Clinical neuropharmacology.

[58]  J. Shih,et al.  A Spontaneous Point Mutation Produces Monoamine Oxidase A/B Knock-out Mice with Greatly Elevated Monoamines and Anxiety-like Behavior*♦ , 2004, Journal of Biological Chemistry.

[59]  M. Youdim,et al.  Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness , 2006, British journal of pharmacology.

[60]  F. Fornai,et al.  Novel aspects of dopamine oxidative metabolism (confounding outcomes take place of certainties). , 2001, Pharmacology & toxicology.

[61]  A. Barbeau.  Dopamine and basal ganglia diseases. , 1961, Archives of neurology.

[62]  M. Muenter,et al.  MAO and L-dopa treatment of Parkinson's disease. , 1990, Journal of neural transmission. Supplementum.

[63]  M. Karayiorgou,et al.  Brain catecholamine metabolism in catechol‐O‐methyltransferase (COMT)‐deficient mice , 2002, The European journal of neuroscience.

[64]  E. Hirsch,et al.  Neuromelanin associated redox‐active iron is increased in the substantia nigra of patients with Parkinson's disease , 2003, Journal of neurochemistry.

[65]  M. da Prada,et al.  Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. , 1995, European journal of pharmacology.

[66]  M. Quik,et al.  Striatal α6* Nicotinic Acetylcholine Receptors: Potential Targets for Parkinson's Disease Therapy , 2006, Journal of Pharmacology and Experimental Therapeutics.